Genmab A/S (NASDAQ:GMAB) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Genmab A/S (NASDAQ:GMAB) have earned an average rating of “Moderate Buy” from the ten brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $45.20.

Several analysts have commented on the stock. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Redburn Atlantic started coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Wednesday, January 8th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th.

Genmab A/S Price Performance

NASDAQ GMAB opened at $20.80 on Tuesday. The stock’s fifty day moving average price is $21.15 and its 200 day moving average price is $24.07. Genmab A/S has a 1 year low of $19.85 and a 1 year high of $31.88. The company has a market cap of $13.76 billion, a price-to-earnings ratio of 20.19, a PEG ratio of 0.59 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). The firm had revenue of $816.10 million during the quarter, compared to analysts’ expectations of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter in the previous year, the business earned $0.47 earnings per share. Research analysts expect that Genmab A/S will post 1.28 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp increased its holdings in Genmab A/S by 4.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 70,171 shares of the company’s stock valued at $1,763,000 after purchasing an additional 3,283 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Genmab A/S by 7.1% in the second quarter. Rhumbline Advisers now owns 18,694 shares of the company’s stock valued at $470,000 after buying an additional 1,236 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Genmab A/S by 360.8% in the 2nd quarter. Acadian Asset Management LLC now owns 38,010 shares of the company’s stock valued at $954,000 after buying an additional 29,762 shares during the period. Headlands Technologies LLC increased its stake in Genmab A/S by 1,702.8% during the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after purchasing an additional 4,853 shares during the period. Finally, Oppenheimer Asset Management Inc. lifted its holdings in Genmab A/S by 26.3% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock worth $5,480,000 after buying an additional 45,376 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.